AngioChem’s ANG1005 For Primary Brain Cancer And Brain Metastasis Selected As A Top 10 Project To Watch
Published: Nov 12, 2013
MONTREAL--(BUSINESS WIRE)--Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced that its most advanced product candidate, ANG1005, a novel paclitaxel-peptide drug conjugate in development for breast cancer patients with brain metastasis and patients with primary brain cancer, has been chosen as one of the Top 10 Oncology Projects to Watch by Elsevier Business Intelligence. Jean E. Lachowicz, Ph.D., Chief Scientific Officer of Angiochem, will provide a summary of ANG1005 during her presentation at the 2013 Therapeutic Area Partnerships conference being held November 18-20, 2013 at the Hyatt Regency, Boston. Dr. Lachowicz’s presentation will take place at 1:30 p.m. ET on Tuesday, November 19, 2013 during the Top 10 Oncology Projects to Watch session.
Help employers find you! Check out all the jobs and post your resume.